WEKO3
アイテム
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
https://repo.qst.go.jp/records/44825
https://repo.qst.go.jp/records/4482505cbf483-9d0d-48f2-a67f-6aafb9e979de
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2007-04-06 | |||||
| タイトル | ||||||
| タイトル | Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Nakamura, Kazutaka
× Nakamura, Kazutaka× Yamaguti, Taketo× Ishihara, Takeshi× Kobayashi, Akitoshi× Tadenuma, Hiroshi× Sudo, Kentaro× Katou, Hirotoshi× Saisho, Hiromitsu× 山口 武人× 加藤 博敏× 税所 宏光 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The objective of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of S-1, an oral fluorouracil derivative, combined with gemcitabine, the current standard treatment for advanced pancreatic cancer (APC). The subjects were histopathologically proven APC patients with distant metastasis. S-1 was administered orally twice daily each day for 14 days and gemcitabine on days 8 and 15 of each cycle, and this was repeated every 21 days. Doses of each drug were planned as follows: level 1: 800/60, level 2a: 800/80, level 2b: 1000/60, level 3: 1000/80 (gemcitabine (mg m(-2))/S-1 (mg m(-2) day(-1))). In all, 21 patients with APC were enrolled. The main grade 3-4 toxicities observed during first cycle were neutropenia (33%), anaemia (10%), thrombocytopenia (14%) and anorexia (10%). There were no DLT observed in level 1. Three of six patients in level 2a had DLT and this level was considered the MTD. In all, 12 patients in level 2b had no DLT and this level was selected as the recommended dose. Applicable responses were one complete response and nine partial responses (48%). As toxicities were well tolerated and antitumour activities seem to be promising, this combination can be recommended for further phase II studies with APC. | |||||
| 書誌情報 |
British Journal of Cancer 巻 92, 号 12, p. 2134-2139, 発行日 2005-12 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0007-0920 | |||||
